Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of ResMed Inc. NYSE: RMD. In a filing disclosed on February 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in ResMed stock on January 13th. The trade occurred in the Representative's "JOINT OWNERSHIP LPL ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of Lowe's Companies NYSE: LOW on 2/7/2025.
- Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 2/3/2025.
- Purchased $1,001 - $15,000 in shares of Take-Two Interactive Software NASDAQ: TTWO on 2/3/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 2/3/2025.
- Purchased $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 1/30/2025.
- Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/30/2025.
- Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 1/29/2025.
- Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 1/29/2025.
- Sold $1,001 - $15,000 in shares of Manhattan Associates NASDAQ: MANH on 1/29/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 1/29/2025.
ResMed Price Performance
Shares of NYSE RMD traded down $2.58 during mid-day trading on Tuesday, hitting $230.41. 285,885 shares of the stock traded hands, compared to its average volume of 954,587. The company has a market cap of $33.84 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 1.57 and a beta of 0.70. ResMed Inc. has a twelve month low of $170.56 and a twelve month high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The firm has a 50 day simple moving average of $238.28 and a two-hundred day simple moving average of $238.99.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, equities research analysts forecast that ResMed Inc. will post 9.44 EPS for the current fiscal year.
ResMed Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed's payout ratio is 25.03%.
Insider Activity
In related news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total transaction of $491,300.00. Following the transaction, the director now directly owns 81,218 shares of the company's stock, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,307 shares of company stock worth $4,403,180 over the last 90 days. 0.71% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. True Wealth Design LLC increased its position in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 110 shares in the last quarter. Colonial Trust Co SC boosted its stake in ResMed by 6,250.0% during the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 125 shares during the last quarter. Optiver Holding B.V. acquired a new position in ResMed during the 4th quarter valued at about $33,000. Ashton Thomas Securities LLC bought a new stake in ResMed during the 3rd quarter worth approximately $34,000. Finally, Itau Unibanco Holding S.A. raised its stake in shares of ResMed by 1,000.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 150 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a report on Friday, January 31st. The Goldman Sachs Group started coverage on shares of ResMed in a research report on Thursday, January 16th. They issued a "buy" rating on the stock. Robert W. Baird upped their target price on ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. UBS Group upgraded ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Finally, Stifel Nicolaus began coverage on ResMed in a research note on Friday, December 13th. They issued a "hold" rating and a $250.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, ResMed presently has an average rating of "Moderate Buy" and an average target price of $244.73.
Read Our Latest Research Report on ResMed
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About ResMed
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Articles
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
